A Study of HIV-infected Subjects Initiating Anti-HIV Drugs for the First Time
Recruitment status was Recruiting
Subjects who are ready to start anti-retroviral therapy (ART) will be screened to see if they are eligible for this study. If interested, patient will enroll in this study the same day they are going to start their ART. A blood sample will be obtained that day before they start ART. This sample will be frozen and sent to a special lab at Argos Therapeutics to be stored until the subject's personalized vaccine can be created. We are not certain that a vaccine can be created for everyone. Subjects will be under no obligation to receive the vaccine if it is made.
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||A Study of HIV-Infected Subjects Initiating HAART for the First Time: A Qualifying Pre-Study for Dendritic Cell Immunization Study|
A frozen plasma sample will be sent to Argos Therapeutics to be stored for possible later use for an autologous dendritic cell HIV-RNA loaded immunization study.
|Study Start Date:||January 2008|
|Estimated Primary Completion Date:||August 2011 (Final data collection date for primary outcome measure)|
|Contact: Sharon Lewis, RN,BSN, CCRNfirstname.lastname@example.org|
|Contact: David Downie, RN,BSNemail@example.com|
|United States, Pennsylvania|
|Drexel University College of Medicine||Recruiting|
|Philadelphia, Pennsylvania, United States, 19102|
|Principal Investigator: Jeffrey M Jacobson, MD|
|Principal Investigator:||Jeffrey M Jacobson, MD||Drexel University College of Medicine|